Targeting RET Kinase in Neuroendocrine Prostate Cancer

The increased treatment of metastatic castration resistant prostate cancer (mCRPC) with second-generation anti-androgen therapies (ADT) has coincided with a greater incidence of lethal, aggressive variant prostate cancer (AVPC) tumors that have lost dependence on androgen receptor (AR) signaling. Th...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Mol Cancer Res
Auteurs principaux: VanDeusen, Halena R., Ramroop, Johnny R., Morel, Katherine L., Bae, Song Yi, Sheahan, Anjali V., Sychev, Zoi, Lau, Nathan A., Cheng, Larry C., Tan, Victor M., Li, Zhen, Petersen, Ashley, Lee, John K., Park, Jung Wook, Yang, Rendong, Hwang, Justin H., Coleman, Ilsa, Witte, Owen N., Morrissey, Colm, Corey, Eva, Nelson, Peter S., Ellis, Leigh, Drake, Justin M.
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415621/
https://ncbi.nlm.nih.gov/pubmed/32461304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-19-1245
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires